Christopher Gibson sold $302k of RXRX
Chief Executive Officer at RECURSION PHARMACEUTICALS, INC.. 40,000 shares at an average of $7.55, traded Nov 13, 2024, filed Nov 15, 2024.
Score components
- +25RoleCEO
- +14Trade size$302k at market
- 0Share of holdings soldSold 5.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.6%, 3m +70.5%, 6m -26.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601830-24-000207, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 782,656 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.74 | $155k | 762,656 | Nov 15, 2024 |
| Nov 14, 2024 | CConversion Class A Common Stock10b5-1 | +20,000 | $0.00 | $0 | 782,656 | Nov 15, 2024 |
| Nov 14, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -20,000 | $7.35 | $147k | 762,656 | Nov 15, 2024 |
| Nov 13, 2024 | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,076,700 | Nov 15, 2024 |
| Nov 14, 2024 | CConversion Class B Common Stockderivative10b5-1 | -20,000 | $0.00 | $0 | 6,056,700 | Nov 15, 2024 |
Related signals
Other insiders at RECURSION PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $242k 50,000 shares | -1% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Robert Hershberg director | $125k 25,000 shares | -13% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $79k 22,408 shares | -1% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $100k 30,000 shares | -0% | |
| 27Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan Chief R&D Commercial Officer | $549k 124,403 shares | -17% | |
| 25Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $180k 40,000 shares | -4% | |
| 25Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $185k 40,000 shares | -4% | |
| 27Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $961k 220,000 shares | -3% | |
| 24Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $166k 40,000 shares | -4% | |
| 17Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $208k 40,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.